# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.98) per share which beat the analyst consensus estimate of ...
HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.
— Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runw...
HC Wainwright & Co. analyst Ed Arce reiterates Assembly Biosciences (NASDAQ:ASMB) with a Neutral.
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interi...